<DOC>
	<DOCNO>NCT02346084</DOCNO>
	<brief_summary>The purpose study evaluate safety , acceptability , PK/PD profile maraviroc gel follow rectal vaginal administration . The study also include oral exposure maraviroc .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study Oral Maraviroc Maraviroc 1 % Gel HIV-1 Seronegative Adults</brief_title>
	<detailed_description>Trail 11991 Phase 1 randomize , open label , single-site trial . Approximately 19 participant ( 9 female , 10 male ) randomize 9 female study arm 4 male study arm 1-3 participant per arm . The randomization complete product sequence time tissue sample collection . All participant receive study product multiple route administration ( i.e. , PO , PR , [ PV female participant ] ) , randomize order product sequence specimen sample schedule . The male participant receive oral rectal MVC female participant receive oral , rectal , vaginal MVC , randomize sequence . Participant accrual take approximately 6 month . Male participant study approximately 9 12 week . Female participant study approximately 12 16 week . The total duration study approximately 9 month .</detailed_description>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>1 . Age 18 45 screening , verify per site SOP 2 . Male participant , born male ; female participant , bear female . 3 . Willing able communicate English 4 . Willing able provide write informed consent take part study 5 . Willing able provide adequate locator information , define site SOP 6 . Availability return study visit , bar unforeseen circumstance 7 . Understands agree local sexually transmit infection ( STI ) reporting requirement 8 . HIV1 seronegative screening enrollment 9 . Must general good health opinion investigator 10 . Willing abstain insertion anything rectum ( e.g. , penis , sex toy , medication , enema ) 72 hour rectal sample visit 72 rectal biopsy visit 11 . Must agree use studyprovided condom insertive receptive intercourse , whether vaginal anal , duration study 12 . Must agree participate concurrent interventional and/or drug trial Female participant must meet following criterion : 13 . Per participant report Screening : 1 . Not pregnant breastfeed 2 . Regular menstrual cycle least 21 day menses 3 . Satisfactory cervical Pap result 24 calendar month prior Enrollment consistent Grade 0 accord Female Genital Grading Table Use Microbicide Studies Addendum 1 DAIDS Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) , satisfactory evaluation treatment require Grade 1 high Pap result per American Society Colposcopy Cervical Pathology ( ASCCP ) guideline 12 calendar month prior Enrollment . 4 . Willing abstain vaginal insertion anything ( e.g. , penis , sex toy , tampon , medication , douche ) 72 hour cervicovaginal sample visit 1 week cervical biopsy visit 14 . Per participant report Enrollment : e ) Using effective method contraception intend continue use effective method duration study participation . Effective method include hormonal method ( except contraceptive vaginal ring ) , intrauterine device ( IUD ) insert least 28 day prior Male participant must meet following criterion : 15 . Per participant report Enrollment : 1 . Using effective method contraception intend continue use effective method duration study participation . Effective method include male condom , surgical sterilization , man identifies man sex men exclusively , sexually abstinent past 90 day , and/or female partner use hormonal contraception , intrauterine device [ IUD ] , surgical sterilization 1 . Undergoing complete gender reassignment 2 . Participant report follow Screening : 1 . Postexposure prophylaxis HIV exposure within 4 week prior screen 2 . Reports history unprotected insertive receptive anal intercourse within 3 month prior screen 3 . History sexually transmit disease last 3 month 4 . Known HIVinfected partner 5 . Nontherapeutic injection drug use 12 month prior screen 6 . History recurrent urticaria 7 . Allergy soy , soybean , peanut , methylparaben , propylparaben , sorbic acid 8 . Use antiretroviral medication activity HIV within 4 week prior Enrollment 9 . Use systemic immunomodulatory medication within 4 week prior Enrollment 10 . Use vaginally rectally administer medication product ( include condom ) contain Nonoxynol9 ( N9 ) within 4 week prior Enrollment 11 . Participating another research study involve drug medical device within 4 week prior Enrollment 12 . Has plan relocate away study site area period study participation 3 . Per participant report screening , anticipate use and/or unwillingness abstain follow medication period study participation : 1 . Heparin , include Lovenox® ( enoxaparin sodium ) 2 . Warfarin 3 . Plavix® ( clopidogrel bisulfate ) 4 . Any drug associate increase likelihood bleeding follow mucosal biopsy ( e.g. , daily high dose aspirin ( &gt; 81 mg ) , NSAIDs , Pradaxa® ) 5 . Rectally vaginally administer medication ( include overthecounter product ) 6 . Use potent CYP3A inhibitor ( e.g. , ketoconazole clarithromycin ) , CYP3A inducer ( e.g. , anticonvulsants St.John 's wort ) 7 . Multiple dose dexamethasone 8 . Antiretroviral medication activity HIV 4 . History significant gastrointestinal bleeding opinion investigator 5 . Abnormalities cervical , vaginal , colorectal mucosa , significant symptom ( ) , opinion clinician represent contraindication protocolrequired biopsy ( include limit presence unresolved injury , infectious inflammatory condition local mucosa , presence symptomatic external hemorrhoid ) . 6 . Body mass index ( BMI ) &lt; 18 &gt; 35 kg/m2 7 . At screening : participantreported symptom , and/or clinical laboratory diagnosis active rectal reproductive tract infection require treatment per current CDC guideline symptomatic urinary tract infection ( UTI ) . Infections require treatment include symptomatic bacterial vaginosis , symptomatic vaginal candidiasis , vaginitis , trichomoniasis , Chlamydia ( CT ) , gonorrhea ( GC ) , syphilis , active HSV lesion , chancroid , pelvic inflammatory disease , genital sore ulcer , cervicitis , symptomatic genital wart require treatment . Note HSV1 HSV2 seropositive diagnosis active lesion allow , since treatment require . Note : In case genital GC/CT identify screening , one rescreening 2 month screen visit allow 8 . Has follow laboratory abnormality Screening : CHARM03 , Version 1.0 28 31st July 2014 1 . Hemoglobin &lt; 10.0 g/dL 2 . Platelet count less 100,000/mm3 3 . White blood cell count &lt; 2,000 cells/mm3 &gt; 15,000 cells/mm3 4 . Calculated creatinine clearance ≤ 70 mL/minute use CockcroftGault equation 5 . Alanine transaminase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5× site laboratory ULN 6 . Total bilirubin &gt; 2.5 ULN 7 . ≥ +1 glucose +2 protein urinalysis ( UA ) 8. International Normalized Ratio ( INR ) test &gt; 1.5× site laboratory upper limit normal ( ULN ) 9 . Positive Hepatitis B surface antigen ( HBsAg ) 10 . Positive Hepatitis C antibody ( HCV Ab ) 11 . CCR5 Δ 32 homozygous heterozygous 9 . Any condition prior therapy , opinion investigator , would preclude informed consent , make study participation unsafe , make individual unsuitable study unable comply study requirement . Such condition may include , limited , current recent history severe , progressive , uncontrolled substance abuse , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral disease In addition criterion list , female participant exclude meet follow criterion : 10 . Participant report follow Screening : 1 . Last pregnancy outcome gynecological surgery 90 day less prior screen 2 . Intends become pregnant period study participation 3 . Chronic and/or recurrent symptomatic vaginal candidiasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>